[Pharmacological approaches to the therapy of Alzheimer's disease].

Gavrilova SI

Vestnik Rossiiskoi akademii meditsinskikh nauk1 Jan 2006

PMID17111921PepBankPUB-17111921

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with Alzheimer's disease, Cerebrolysin had a significant therapeutic effect.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin had a significant therapeutic effect.
Peptide
Cerebrolysin
Outcome
IncreaseTherapeutic effect
Study
n: not reported in source
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30.0 ml · i.v. · four monthsAs given in this study (human).
Source sentences
Summary
Both treatments had a significant therapeutic effect, but the proportion of responders to different kinds of therapy depended on ApoE genotype.
2 context sentences(design, population, supporting numbers)
Summary · context
The role of apolipoprotein E (ApoE) genotype in the forming of response to various kinds of pathogenetic therapy of Alzheimer's disease (AD) was studied in two samples of patients receiving cholinergic or neurotrophic therapy during four months.
Summary · context
Patients in group II received two courses of cerebrolysin (20 i.v. injections of 30.0 ml of the drug in 100 ml of normal saline) with an 8-week break.
Report a problemFND-1711192101
02HumanNon-randomized trialEfficacy outcome
In ApoEepsilon4-positive patients with Alzheimer's disease, responder proportions were practically equal with Cerebrolysin and exelon (30.8% and 31.2%).
In plain wordsIn patients with Alzheimer's disease and ApoEepsilon4, response rates were similar with Cerebrolysin and exelon.
Peptide
Cerebrolysin
Outcome
No significant changeResponders in ApoEepsilon4-positive patients
Study
n: not reported in source
Comparator
Exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30.0 ml · i.v. · four monthsAs given in this study (human).
Measurements
Proportion of responders
30.8%
ApoEepsilon4(+) patients, first reported treatment-group proportion, arm unspecified in this sentence
Proportion of responders
31.2%
ApoEepsilon4(+) patients, second reported treatment-group proportion, arm unspecified in this sentence
Source sentences
Summary
Among ApoEepsilon4(+) patients the proportion of responders was practically equal in both treatment groups (30.8% and 31.2%)
2 context sentences(design, population, supporting numbers)
Summary · context
The role of apolipoprotein E (ApoE) genotype in the forming of response to various kinds of pathogenetic therapy of Alzheimer's disease (AD) was studied in two samples of patients receiving cholinergic or neurotrophic therapy during four months.
Summary · context
Patients in group II received two courses of cerebrolysin (20 i.v. injections of 30.0 ml of the drug in 100 ml of normal saline) with an 8-week break.
Report a problemFND-1711192102
03HumanNon-randomized trialEfficacy outcome
In ApoEepsilon4-negative patients with Alzheimer's disease, response rates were higher with Cerebrolysin than exelon (47.0 and 14.3%, respectively).
In plain wordsIn patients with Alzheimer's disease without ApoEepsilon4, response rates were higher with Cerebrolysin than exelon.
Peptide
Cerebrolysin
Outcome
IncreaseResponders in ApoEepsilon4-negative patients
Study
n: not reported in source
Comparator
Exelon
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30.0 ml · i.v. · four monthsAs given in this study (human).
Measurements
Proportion of responders
47%
ApoEepsilon4(-) patients, cerebrolysin group
Proportion of responders
14.3%
ApoEepsilon4(-) patients, exelon group
Ratio of responder proportions
3 times
ApoEepsilon4(-) patients, cerebrolysin versus exelon
Source sentences
Summary
while among ApoEepsilon4(-) patients the proportion of responders to cerebrolysin was three times as big as the proportion of responders to exelon (47.0 and 14.3%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The role of apolipoprotein E (ApoE) genotype in the forming of response to various kinds of pathogenetic therapy of Alzheimer's disease (AD) was studied in two samples of patients receiving cholinergic or neurotrophic therapy during four months.
Summary · context
Patients in group II received two courses of cerebrolysin (20 i.v. injections of 30.0 ml of the drug in 100 ml of normal saline) with an 8-week break.
Report a problemFND-1711192103
04HumanNon-randomized trialEfficacy outcome
In Cerebrolysin-treated patients with Alzheimer's disease, response was 1.5 times more frequent without ApoEepsilon4 than with ApoEepsilon4.
In plain wordsIn patients with Alzheimer's disease, Cerebrolysin response was more frequent without ApoEepsilon4 than with ApoEepsilon4.
Peptide
Cerebrolysin
Outcome
IncreaseResponse by ApoE genotype
Study
n: not reported in source
Comparator
ApoEepsilon4-positive Cerebrolysin patients
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30.0 ml · i.v. · four monthsAs given in this study (human).
Measurements
Ratio of responder proportion, ApoEepsilon4(-) versus ApoEepsilon4(+)
1.5 times
cerebrolysin group
Source sentences
Summary
In the cerebrolysin group the proportion of responders was 1.5 times bigger among ApoEepsilon4(-)patients
2 context sentences(design, population, supporting numbers)
Summary · context
The role of apolipoprotein E (ApoE) genotype in the forming of response to various kinds of pathogenetic therapy of Alzheimer's disease (AD) was studied in two samples of patients receiving cholinergic or neurotrophic therapy during four months.
Summary · context
Patients in group II received two courses of cerebrolysin (20 i.v. injections of 30.0 ml of the drug in 100 ml of normal saline) with an 8-week break.
Report a problemFND-1711192104
05HumanNon-randomized trialEfficacy outcome
In patients with Alzheimer's disease, Cerebrolysin effects two months after treatment were higher without ApoEepsilon4 than with ApoEepsilon4.
In plain wordsIn patients with Alzheimer's disease, lasting Cerebrolysin effects were higher without ApoEepsilon4 than with ApoEepsilon4.
Peptide
Cerebrolysin
Outcome
IncreaseLong-term effect by ApoE genotype
Study
n: not reported in source
Comparator
ApoEepsilon4-positive Cerebrolysin patients
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30.0 ml · i.v. · four monthsAs given in this study (human).
Source sentences
Summary
Long-term effects of cerebrolysin (two months after the end of the treatment) in ApoEepsilon4(-) patients were also higher than those in ApoEepsilon4(+) patients
2 context sentences(design, population, supporting numbers)
Summary · context
The role of apolipoprotein E (ApoE) genotype in the forming of response to various kinds of pathogenetic therapy of Alzheimer's disease (AD) was studied in two samples of patients receiving cholinergic or neurotrophic therapy during four months.
Summary · context
Patients in group II received two courses of cerebrolysin (20 i.v. injections of 30.0 ml of the drug in 100 ml of normal saline) with an 8-week break.
Report a problemFND-1711192105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.